Company Overview and News

6
CLVS / Clovis Oncology, Inc. 8-K (Current Report)

20h sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.
Upvote Downvote

 
Gene–Drug Interaction Map Developed to Aid Personalized Chemotherapy

2018-04-18 genengnews
Researchers at the University of California, San Francisco (UCSF) have generated a detailed, quantitative gene–drug interaction map as an open resource that could help clinicians prescribe the most effective type of chemotherapy for each cancer patient, based on the tumor’s genetic profile.
Upvote Downvote

1
Your Daily Pharma Scoop: GW Pharmaceuticals' Epidiolex, Alnylam Data, Johnson & Johnson's Q1 Results

2018-04-18 seekingalpha
Today, we will discuss GW Pharmaceuticals (NASDAQ:GWPH), which is up more than 10% after the FDA released briefing documents ahead of the Ad Com meeting to review GWPH's NDA for Epidiolex for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS) in patients 2 years or older.
Upvote Downvote

1
CLVS / Clovis Oncology, Inc. 424(B)(5) (Prospectus)

2018-04-17 sec.gov
424(b)(5) Table of Contents Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-215400 CALCULATION OF REGISTRATION FEE
Upvote Downvote

5
CLVS / Clovis Oncology, Inc. 424(B)(5) (Prospectus)

2018-04-17 sec.gov
424(b)(5) Table of Contents Filed pursuant to Rule 424(b)(5) Registration No.: 333-215400 CALCULATION OF REGISTRATION FEE
Upvote Downvote

3
CLVS / Clovis Oncology, Inc. FWP

2018-04-17 sec.gov
FWP Free Writing Prospectus Filed pursuant to Rule 433 Registration Statement No. 333-215400 Dated April 16, 2018
Upvote Downvote

 
Your Daily Pharma Scoop: Blueprint Medicines' BLU-667, Gilead Sciences' NASH Data, Celldex's Plunge

2018-04-17 seekingalpha
Today we will discuss Blueprint Medicines (BPMC), which is down more than 12% after reporting data from a phase 1 study with BLU-667 in RET-altered solid tumors. The phase 1 study was a proof-of-concept study.
Upvote Downvote

6
CLVS / Clovis Oncology, Inc. FWP

2018-04-17 sec.gov
FWP Free Writing Prospectus Filed pursuant to Rule 433 Registration Statement No. 333-215400 Dated April 16, 2018
Upvote Downvote

 
BRIEF-Clovis Oncology Announces Pricing Of Public Offerings Of Convertible Senior Notes And Common Stock

2018-04-17 reuters
* CLOVIS ONCOLOGY INC- PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF $300 MILLION AGGREGATE PRINCIPAL AMOUNT OF ITS 1.25% CONVERTIBLE SENIOR NOTES DUE 2025
Upvote Downvote

3
CLVS / Clovis Oncology, Inc. FWP

2018-04-16 sec.gov
FWP Issuer Free Writing Prospectus dated April 16, 2018 Filed Pursuant to Rule 433 Relating to Preliminary Prospectus Supplement dated April 16, 2018 Registration No. 333-215400
Upvote Downvote

1
CLVS / Clovis Oncology, Inc. 424(B)(5) (Prospectus)

2018-04-16 sec.gov
424(b)(5) Table of Contents Filed pursuant to Rule 424(b)(5) Registration No.: 333-215400 The information in this prospectus supplement is not complete and may be changed. This prospectus supplement and the accompanying prospectus is not an offer to sell these securities in any
Upvote Downvote

2
CLVS / Clovis Oncology, Inc. 424(B)(5) (Prospectus)

2018-04-16 sec.gov
424(b)(5) Table of Contents Filed pursuant to Rule 424(b)(5) Registration No.: 333-215400 The information in this prospectus supplement is not complete and may be changed. This prospectus supplement and the accompanying prospectus is not an offer to sell these securities in any state or other jurisdiction where the offe
Upvote Downvote

3
CLVS / Clovis Oncology, Inc. POSASR

2018-04-16 sec.gov
POSASR Table of Contents As filed with the Securities and Exchange Commission on April 16, 2018 Registration No. 333- 215400
Upvote Downvote

 
3 Stocks to Buy Now With Up to 100% or More Upside Potential

2018-04-11 247wallst
One reason that investors continue to do business with full-service brokerage firms is they generate investment ideas, and when they make a call, they typically have solid reasons and a good thesis to back it up, regardless of whether the ideas is long or short.
Upvote Downvote

 
Biotech Analysis Central Pharma News: Novartis's Gene Therapy Catch, AstraZeneca's NASH Move, Clovis's Expanded Rubraca Market

2018-04-11 seekingalpha
Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 189464100